From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

As you get closer, the image becomes clear and you unconsciously hold your breath. It’s a black cat out for its morning stroll. You pause for a second to decide your next move. Cross the street ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

This Is Lorelei, Black Country New Road, Cassandra Jenkins, and many more. It’s also the first-announced Europe show for the newly-reunited Cap’n Jazz, whose booking agent recently teased a ...

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $84.00. Terence Flynn’s rating is based on ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II ...